Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter Study.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.

Ji, Jingran; Aredo, Jacqueline V; Piper-Vallillo, Andrew; Huppert, Laura; Rotow, Julia K; Husain, Hatim; Stewart, Susan; Cobb, Rosemary; Wakelee, Heather A; Blakely, Collin M; Wong, Melisa L; Gubens, Matthew A; Madani, Mohammad H; Digumarthy, Subba R; McCoach, Caroline; Piotrowska, Zofia; Neal, Joel W; Riess, Jonathan W.

Afiliação

Ji J; City of Hope Comprehensive Cancer Center, Duarte, California.
Aredo JV; UC Davis Comprehensive Cancer Center, Sacramento, California.
Piper-Vallillo A; Stanford Cancer Institute, Stanford, California.
Huppert L; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Rotow JK; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California.
Husain H; Dana-Farber Cancer Institute, Boston, Massachusetts.
Stewart S; UCSD Moores Comprehensive Cancer Center, La Jolla, San Diego, California.
Cobb R; UC Davis Comprehensive Cancer Center, Sacramento, California.
Wakelee HA; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Blakely CM; Stanford Cancer Institute, Stanford, California.
Wong ML; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California.
Gubens MA; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California.
Madani MH; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California.
Digumarthy SR; UC Davis Comprehensive Cancer Center, Sacramento, California.
McCoach C; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Piotrowska Z; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California.
Neal JW; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Riess JW; Stanford Cancer Institute, Stanford, California.